Targeting Tumor Metabolism and Epigenetics: Mechanisms and Therapeutic Strategies

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Metabolism".

Deadline for manuscript submissions: 22 May 2025 | Viewed by 135

Special Issue Editors


E-Mail Website
Guest Editor
INSERM U993, Unité Organisation Nucléaire et Oncogenèse, Institut Pasteur, Université Paris Cité, 75006 Paris, France
Interests: metabolism; epigenetics; cancer; hepatoblastoma; liver cancer

E-Mail Website
Guest Editor
Brain Plasticity Unit, CNRS, ESPCI Paris, PSL Research University, 75006 Paris, France
Interests: metabolism; epigenetics; energy; medulloblastoma; memory

E-Mail Website
Guest Editor
Anatomy & Cell Biology Department, School of Medicine, University of Cantabria, 39011 Santander, Spain
Interests: epigenetics; nucleous; nanoparticles; neurodegeneration; cancer

Special Issue Information

Dear Colleagues,

Recent advances in cancer research have highlighted the critical role of metabolic and epigenetic reprogramming in driving tumorigenesis and therapeutic resistance. Tumor cells often exhibit altered metabolic pathways, including heightened glycolysis, oxidative phosphorylation modulation, and lipid synthesis adaptations, to sustain rapid proliferation and evade cellular death. These metabolic shifts, collectively known as metabolic reprogramming, not only fuel tumor growth but also create an environment conducive to immune evasion and metastatic progression. Concurrently, epigenetic modifications, such as DNA methylation, histone modification, and chromatin remodeling, play pivotal roles in silencing tumor suppressor genes and activating oncogenes, thus reinforcing malignancy at a cellular level. These modifications are often influenced by metabolic intermediates, suggesting a tightly regulated crosstalk between metabolic and epigenetic pathways that sustains tumor cell survival and adaptability.

Targeting these dual mechanisms offers a promising therapeutic approach. Metabolic inhibitors, such as glycolysis blockers and inhibitors of fatty acid synthesis, are currently in various stages of clinical evaluation. Similarly, epigenetic drugs targeting DNA methyltransferases and histone deacetylases have shown potential in preclinical models and clinical trials. This Special Issue seeks to gather cutting-edge research and reviews on the underlying mechanisms of tumor metabolism and epigenetics, and to explore therapeutic strategies that target these interconnected pathways. The goal is to provide a comprehensive understanding of how targeting these processes could lead to more effective cancer treatments and personalized therapy approaches, particularly in tumors resistant to conventional therapies.

Dr. Jorge Mata-Garrido
Dr. Raquel Francés
Dr. Íñigo Casafont
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor metabolism
  • epigenetics
  • metabolic reprogramming
  • DNA methylation
  • histone modification
  • warburg effect
  • glycolysis inhibitors
  • fatty acid synthesis
  • chromatin remodeling
  • cancer therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop